BRAF and Miyoshi myopathy: However, the effectiveness of these targeted and non-targeted immune-based strategies has been poor for MMs lacking the BRAF mutation and for rare MM subtypes, including the uveal, acral, and mucosal MM subtypes, due to either primary or acquired resistance following initial treatment [8].